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Summary 
The recently published European Guidelines for the Management of Bronchiectasis in adults highlight 
the limited treatment options available for these patients. There remain no therapies licensed by 
regulatory agencies worldwide and most therapies used in clinical practice have very limited evidence. 
There is an urgent need to develop new therapies.  
Using a systematic review of the literature and clinical trials registries we identified therapies in early to 
late clinical development for bronchiectasis in adults. This article presents a discussion of the 
mechanisms and potential role of emerging therapies, including drugs targeting airway and systematic 
inflammation, mucociliary clearance and epithelial dysfunction.  
To ensure these therapies achieve success in randomized clinical trials and therefore reach patients, we 
propose a re-evaluation of our current approach to bronchiectasis. Although our understanding of the 
pathophysiology of bronchiectasis is at an early stage, we argue that bronchiectasis is a heterogeneous 
disease with multiple different biological mechanisms driving disease progression (endotypes) and 
therefore the “treatable traits” concept of asthma and COPD could be applied to bronchiectasis with 
future trials targeted at specific subgroups most likely to benefit. 
Key Points Panel 
1-In the recent European Bronchiectasis Guidelines, no pharmacotherapy was supported by strong 
clinical evidence  
2-Multiple recent trials in bronchiectasis have focussed on antibiotic treatment and have failed to 
reach their primary end-points, suggesting a need to re-evaluate how we use and test therapies in 
bronchiectasis patients.  
3-New therapeutic development in bronchiectasis is focussed an modulating inflammatory processes, 
including targeting neutrophil, macrophage, T-cell and epithelial function to reverse the underlying 
disease processes. 
4- Bronchiectasis is a heterogeneous disease incorporating multiple different aetiologies, with 
different radiological, microbiological, inflammatory and physiological subgroups, referred to as 
phenotypes and endotypes 
5-We propose that a “one size fits all” approach to clinical trials and clinical practice in bronchiectasis 
is unlikely to be successful. Instead, we suggest that the “treatable traits” concept of airways disease 
could be applied to bronchiectasis to improve therapeutic targeting both in clinical trials and in clinical 
practice.   
Introduction 
“This is the age of bronchiectasis”.1 The prevalence of bronchiectasis in the UK increased by 40% between 
2004 and 2014 with similar increases observed worldwide.2 The increasing recognition of the disease is 
multifactorial including a greater use of CT scanning, greater physician awareness and the recognised 
overlap between bronchiectasis, asthma and COPD .3 The increasing burden of the disease on the 
healthcare system has  led to a surge in clinical research, new randomized trials and a global growth in 
specialist services.4-10 
 
Great progress has been achieved and the profile of bronchiectasis within respiratory medicine has never 
been higher. In September 2017, the first European Guidelines for adult bronchiectasis were published .4 
These guidelines represent  the first international standards of care for the disease that follow  a number 
of national guidelines produced in the past decade.4,5 The publication of these guidelines while an 
important milestone, illustrate  how far we remain to travel to deliver effective therapies to patients. 
Of the key treatment recommendations only 1 was supported by high quality evidence:  pulmonary 
rehabilitation.4 Most recommendations were conditional and based on low or very low quality of evidence 
(table 1).4 
 
 
 
There remains no therapy licensed by regulatory authorities worldwide for the treatment of 
bronchiectasis despite a large number of phase 3 randomized clinical trials. This contrasts with other 
conditions, notably idiopathic pulmonary fibrosis which have experienced a similar renaissance but where 
positive phase 3 trials have led to the licensing of new drugs and a positive impact on patients outcomes.11 
The repeated failure of trials in bronchiectasis to give positive outcomes necessitates a re-evaluation of 
our approach10,11-15  
 
In this review,  we outline novel approaches to the management of bronchiectasis in adults aiming to take 
us beyond antibiotics and beyond the recommended therapies  in  recent  guidelines.4 Furthermore, we 
propose  that recent randomized trials have struggled to show clinical benefits because of the unresolved 
heterogeneity of bronchiectasis, and that a more logical, stratified approach to therapy will be required 
going forward.16 In this light, we offer newer perspectives on strategies to achieve patient stratification 
that in future, will likely make the disease more amenable to personalised care.    
 
Search strategy and selection criteria 
The authors performed a review using PUBMED of all manuscripts published using the keyword 
“bronchiectasis” since January 2010 to September 2017. As the objective of the review was to identify 
novel treatment approaches entering clinical trials for adults, the authors searched the international 
clinical trial registries ISCRTN and clinicaltrials.gov using the search term “bronchiectasis”. Randomized 
clinical trials were selected for discussion based on relevance. The clinical trial registry search identified 
172 current randomized controlled trials in bronchiectasis or where bronchiectasis is mentioned as a 
target indication with 55 actively enrolling. Below we review potential therapeutic approaches to 
bronchiectasis in early to late clinical development. 
 
 
Recent randomized clinical trials  
The majority of late phase randomized clinical trials to be conducted in bronchiectasis have involved 
attempts to translate therapies licensed in cystic fibrosis (CF). The first example where this failed was a 
1998 trial of recombinant DNAse which showed an increased frequency of exacerbations (relative risk 
1.35 95%CI 1.01-1.79), and increased adverse events in the DNAse treated patients.15 Recent trials have 
confirmed the view that “CF drugs” cannot easily be translated for bronchiectasis.10,12,13 Inhaled dry 
powder mannitol was tested in a trial of 461 patients with bronchiectasis. The study failed to reach its 
primary end-point of frequency of exacerbations (rate ratio 0.92,p=0.3) although improvements for  
secondary end-points of time to the first exacerbation and health related quality of life were seen.10 The 
development of inhaled antibiotics has dominated the clinical trial scene in bronchiectasis in recent years 
with mixed results. Small studies of tobramycin and gentamicin showed positive results but were 
complicated by relatively high (10-40%) rates of bronchospasm, and to date, these drugs have not been 
tested in large studies.17,18 Among  larger phase 3 trials, Haworth et al recruited 144 patients with chronic 
P. aeruginosa infection and randomized patients to nebulised colistin or placebo.12 The study narrowly 
failed to meet its primary end-point of time to the first exacerbation (difference colistin vs placebo of 54 
days; p=0.11). Among  secondary end-points, a large improvement in quality of life using the SGRQ was 
noted (mean difference −10.5 points; p=0.006).12 This study most likely failed to meet its primary end-
point due to slow recruitment leading to premature termination of the trial.12 Aztreonam is another  
inhaled antibiotic licensed for treatment in CF. Two recent phase III trials in bronchiectasis randomised 
266 (AIR-BX1) and 274 (AIR-BX2) patients to aztreonam 75mg three times daily or placebo over the course 
of two 28-day treatment cycles (with 28-days off treatment between cycles).13 The primary outcome was 
the newly developed Quality of Life Bronchiectasis (QoL-B) questionnaire.13 The trial found a significant 
change in the QOL-B respiratory symptom score in AIR-BX2 but not in AIR-BX1. Treatment related adverse 
effects and their associated discontinuations were increased in the Aztreonam treated patients.13 Reasons 
for the failure of this study to meets its end-point has been the subject of speculation with likely  
explanations including  the highly heterogeneous study population  with many patients having no history 
of exacerbations and relatively mild disease.13  The characteristics of  included patients included high rates 
of pulmonary non-tuberculous mycobacterial disease and COPD. Nadig and Flume compared the 
characteristics of included patients in this study to their own population of severe patients with 
bronchiectasis treated with inhaled antibiotics and identified little correlation, suggesting that the trial 
included a skewed population  not representative of ‘real-life’ clinical practice.19  
 
Most recently two large programmes developing different inhaled ciprofloxacin formulations have 
reported.20,21 At the time of writing neither study has  been reported fully, but published abstracts show 
that liposomal ciprofloxacin achieved its primary end-point (time to the first exacerbation) in one 
international RCT (ORBIT 4) for patients with Pseudomonas aeruginosa infection and a history of at least 
2 exacerbations - HR 0.72 95% CI 0.53-0.97,p=0.03, but failed to achieve the primary end point in the 
replicate ORBIT 3 trial, HR 0.99 95% CI 0.71-1.38,p=0.97.20 Pooled data from the total 582 patients showed 
a significant reduction in time to first exacerbation requiring antibiotics, HR 0.74 95% CI 0.59-0.94,p=0.01 
and also a significant reduction in the frequency of exacerbations, relative risk 0.73 95% CI 0.60-
0.88,p=0.001.20 
 
Dry powder ciprofloxacin was tested in 2 x 2 arm trials, each utilising a 14-day on/off and a 28 day on/off 
regimen. The RESPIRE 1 study included 416 patients and found that the 14-day on/off regimen prolonged 
time to first exacerbation, HR 0.53 97.5% CI (0.36-0.80,p=0.0005) and also frequency of exacerbations, 
incidence rate ratio 0.61 97.5% CI (0.40-0.91,p=0.006).21 The 28-day on/off regimen had no significant 
benefit in either end-point. The RESPIRE 2 studies enrolled 521 patients and failed to show a statistically 
significant improvement in time to first exacerbation or frequency of exacerbations in either arm. RESPIRE 
2 was conducted primarily in Asia and Eastern Europe, and found a very low rate of exacerbations 
(approximately 0.6 per patient/year) despite enriching for patients with chronic bacterial infection and at 
least 2 exacerbations in the prior year.21 
 
Therefore, while many therapies, including antibiotics, mucoactive drugs and others have shown trends 
toward benefit, none have unequivocally demonstrated improvement in clinical outcomes. Even where 
improvements of 20-40% in exacerbation frequency are demonstrated, these represent only a modest 
improvement in outcomes for a disease which often has a devastating effect on quality of life.  
The one notable success in bronchiectasis therapy in the past 5 years has been macrolides. 3 trials of 
azithromycin (2 in adults and 1 in children) and 1 trial of erythromycin showed a significant reduction in 
the frequency of exacerbations of approximately 50% compared to placebo.22-25 Nevertheless, these trials 
were relatively small with the largest including 71 patients treated with azithromycin vs 70 patients 
receiving placebo.22-25 Their success in reaching their primary endpoints may relate to the inclusion of 
patients from a small number of centres in a single region, allowing more homogeneous populations to 
be included. The lack of large scale trials and the associated risk of side effects and antibiotic resistance 
explains the conditional recommendation for their use in the ERS guidelines.4 
New treatments approaches are clearly necessary and, importantly, new ways of performing clinical trials 
should be considered to overcome the persistent difficulty in achieving positive results. Future studies 
need to better address patient classification, stratification and our understanding of disease mechanisms. 
This will, in turn, influence inclusion criteria for clinical trials which to clearly need to be aiming to deliver 
the ‘right treatment to the right patient’ rather than the status quo of assessing treatments across a large 
heterogeneous patient group. The optimal trial endpoints still need to be defined.26 The frequency of 
exacerbations is the most robust and clinically important, but the responsiveness and validity of the QOL-
B is still to be established. FEV1 is a responsive endpoint in CF but does not change at exacerbation or 
during therapy in bronchiectasis.26 There is a need to identify better surrogate endpoints specifically for 
bronchiectasis. 
 
Novel treatment approaches 
The treatment of CF is being transformed by the availability of therapies that target the basic defect.28 A 
challenge in bronchiectasis not due to CF is the lack of a basic understanding of why patients develop 
disease. At present, a therapy targeting the basic defect is only possible in cases with a clearly defined 
reversible cause such as immunodeficiency, allergic bronchopulmonary aspergillosis or non-tuberculous 
mycobacterial disease.28 For most however, no identifiable cause is found.4 While the concept of 
preventing bronchiectasis in patients with persistent bacterial bronchitis in childhood has gained 
acceptance in children, the equivalent concept has not yet been accepted in adults.29  
 
New therapeutic development is therefore centred around three components of the “vicious cycle”, 
namely targeting bacterial infection (as discussed above), neutrophilic inflammation and mucociliary 
clearance. A summary of non-antibiotic therapies in development for bronchiectasis are shown in figure 
1. Current randomized controlled trials of non-antibiotic drug therapies are summarised in table 2. 
 
Targeting the neutrophil 
Neutrophils are the dominant airway inflammatory cell  in the majority of bronchiectasis patients.30 
Patients show elevated numbers of neutrophils and other inflammatory cells compared to healthy 
controls and consequently show elevated levels of  neutrophil derived products such as neutrophil 
elastase (NE), myeloperoxidase, matrix metalloproteinases, cathepsins, antimicrobial peptides (such as 
LL-37) and neutrophil derived DNA.30-32 The limited available studies  suggest that bronchiectasis patients 
neutrophils are essentially normal prior to arriving in the airway but that changes occur in the airway 
environment that promote neutrophil dysfunction and a failure of bacterial clearance.33,34 This is unlikely 
to be true in all patients, as neutrophil defects have been identified in patients with CF , including 
abnormal degranulation and delayed neutrophil apoptosis, both of which can be reversed by CFTR 
correctors.35,36 Abnormal neutrophil chemotaxis is also shown in systematic neutrophils from COPD 
patients.37 Further study  is required to delineate similar defects in neutrophils from bronchiectasis 
patients. Airway neutrophil dysfunction in bronchiectasis may result from a combination of host derived 
mediators, bacterial virulence factors, and changes induced by “frustrated” attempts to clear biofilm 
shielded bacteria. Studies from the 1980’s and 90’s suggested a key role for neutrophil elastase in 
mediating neutrophil dysfunction, through cleavage of multiple cell surface receptors such as CR1, 
FCYRIIIb, CXCR1 and others involved in phagocytosis.30 NE is  thought to  slow ciliary beat frequency, 
promote mucus production , impair clearance of apoptotic cells and confer  downstream effects on 
activation of other proteases such as MMPs.38-40 Elastase is  critical to initiating the process of neutrophil 
extracellular trap formation- a form of cell death  enhanced in chronic lung disease resulting in the active 
extrusion of DNA and toxic neutrophil granule products.41  
 
NE inhibition is therefore a potentially logical approach in bronchiectasis. Oral and inhaled preparations 
of NE inhibitor compounds are in clinical development while two oral NE inhibitors have been already 
trialled in bronchiectasis patients.42-44 AZD9668 was tested in 38 patients over 28 days. The primary 
outcome of reducing sputum neutrophil counts was not achieved, but there was a statistically significant 
100ml increase in FEV1 and promising trends in quality of life using the SGRQ.43  A study of 94 patients 
with the NE inhibitor BAY85-8501 showed no evidence of efficacy in bronchiectasis and has only been 
reported in abstract form.44 This is not a promising background against which to develop new drugs, but 
these studies do not necessarily invalidate the approach of inhibiting NE. For instance, 28-days may be 
too short a duration to demonstrate effectiveness for an anti-inflammatory treatment; macrolides 
reduced exacerbations and improved quality of life over 6-12 months in bronchiectasis, but these trials 
would have been negative if stopped at day 28.22-25 Further, no evidence has been shown to indicate that 
the administered doses of AZD9668 or BAY85-8501 were sufficient to inhibit sputum NE activity in 
bronchiectasis patients. 
 Support for the concept that NE may be important in bronchiectasis disease progression has recently been 
provided by a UK study of 433 patients.30 In this cohort elevated sputum NE activity was associated with 
a higher exacerbation frequency and a more rapid decline in FEV1. 30 An important finding of this study, 
however, was that 1/3  of patients with bronchiectasis did not have active sputum NE at baseline.30 If this 
were replicated in the above clinical trials, they may be grossly underpowered to illustrate any clinical 
benefits on the assumption that patients without active NE could not be expected to respond to inhibitor 
therapy. This argues for a “personalized medicine” approach to future trials of anti-neutrophil therapy.  
 
Cathepsin C/ dipeptidyl-peptidase I inhibition (DPP1) 
An alternative approach to traditional NE inhibition is the use of inhibitors that target the activation of 
serine proteases in the bone marrow.45 DPP1 is a lysosomal cysteine protease that cleaves NE, cathepsin 
G and proteinase-3, activating them during neutrophil maturation.45 Activated neutrophil serine proteases 
are then packaged into granules before the mature neutrophils are released into the systemic circulation. 
DPP1 inhibitors therefore could theoretically abolish neutrophil serine protease activity in the airway at 
source.  
Two DPP1 inhibitors are currently identified in the clinicaltrials.gov database as being in development for 
bronchiectasis.46 
Challenges in the development of DPP1 inhibitors reflect the difficult balance that must be achieved in 
inhibiting neutrophil functions. Neutrophils are unquestionably damaging in the context of chronic 
inflammation but are also required for host defence in multiple tissues. Mutations that inactivate the 
DPP1 gene in humans result in an immunodeficiency called Papillon-Lefevre syndrome (PLS).47 PLS is 
characterised by palmoplantar keratoderma and periodontitis. The latter results in the loss of all teeth 
during childhood.47 
Initial human trials have now been conducted with DDP1 inhibitors. GSK2793660 was administered to 
healthy male subjects in a phase 1 trial with escalating doses.48 While only modest reductions in neutrophil 
protease activity in blood were observed (approximately 20%) 7 out of 10 subjects in the trial manifested 
palmar/plantar epidermal desquamation.48 A single, followed by multiple ascending dose study of the 
reversible DPP1 inhibitor AZD7986 achieved reductions in plasma NE activity of up to 50% at the highest 
tested doses. 5 patients in the cohort manifested mild exfoliation of the palms and soles which reversed 
after treatment discontinuation.49 A phase 2 trial in patients with bronchiectasis has recently been 
initiated.50  
 
 While this mechanism appears promising, the potential adverse effects represent a challenge for large 
scale testing in RCTs. Patients in longer studies would require careful assessment of dental and skin health. 
All studies targeting immune responses in bronchiectasis suffer from the challenge of trying to identify 
“the goldilocks zone” where inflammation is suppressed sufficiently to improve clinical outcomes without 
overtly suppressing host defence such that infectious complications develop.  
 
CXCR2 antagonism 
A further approach to reducing neutrophilic inflammation is to directly reduce the number of neutrophils 
entering tissues by preventing chemotaxis, or to reduce inflammation by preventing or reducing 
neutrophil activation. CXCR2 is a chemokine receptor, activated by binding of CXCL1 and CXCL8. 
Antagonism of CXCR2 has been shown to reduce lung neutrophil recruitment  without impairing  
phagocytosis or oxidative burst, activities  partially  mediated through CXCR1.51 A single clinical trial has 
been completed in bronchiectasis with oral administration of AZD5069 80mg twice daily.14 In 45 patients 
completing treatment, this therapy reduced sputum neutrophil numbers by 69%  with no difference in 
the small number of exacerbations over 28 days follow-up.14 There were 4 infection-related 
discontinuations in the AZD5069 group (1 due to pneumonia and 3 exacerbations of bronchiectasis) with 
none in the placebo group.14  Studies in humans and non-human primates illustrate  an increase in blood 
cytokines with treatment including the CXCR2 ligands CXCL8 and CXCL1.14 The clinical significance of this 
is  unknown. Again, 28 days is likely to be too short a period to evaluate clinically relevant effects and 
larger studies are needed. Additional CXCR2 antagonist compounds are in current clinical development.52  
 
Immunomodulatory drugs 
Inflammation in bronchiectasis is complex and it is uncertain that targeting neutrophils alone will be 
sufficient to improve clinical outcomes. A number of additional anti-inflammatory therapies with a wide 
range of clinical effects are in development or have been tested.  
 
Vitamin D 
Vitamin D receptors are found on the majority of inflammatory cells.32 Vitamin-D has broad-spectrum 
anti-inflammatory effects, suppressing cytokine production, promoting LL-37  secretion  from epithelial 
cells and enhancing P. aeruginosa killing.53 In-vitro observations with vitamin-D have not always translated 
into clinically meaningful benefits in other diseases.54 A UK study found that 50% of bronchiectasis 
patients had vitamin-D deficiency with the most deficient subjects illustrating higher rates of bacterial 
infection (including  P. aeruginosa), and a higher rate of exacerbations.32 Association does not prove 
causation however, and it is not known if replacement of vitamin-D would improve clinical outcomes in 
bronchiectasis. Trials of replacement therapy are ongoing and will provide evidence to suggest either a 
causal association, or whether vitamin D deficiency is a consequence of chronic illness and the 
accompanying lack of exposure to outdoor sunlight.55 Trials of vitamin-D replacement are challenging 
since optimal concentration and replacement dose are unknown.  
 
GM-CSF  
Granulocyte-macrophage colony stimulating factor is a glycoprotein secreted by macrophages, T-cells, 
mast cells, NK cells and epithelial cells and has diverse effects on neutrophils, macrophages and 
eosinophils.33 Non-tuberculous Mycobacteria represent a challenging subgroup of bronchiectasis mostly  
associated with Mycobacterium avium and requiring prolonged treatment with antibiotics.56 Success with 
>1 year of antibiotic therapy in clearing M. avium from sputum varies from 13-86% in reported series. 
Therefore adjunctive therapy to antibiotics may carry significant benefits. Exogenous GM-CSF in-vitro has 
been shown to enhance intracellular killing of M. avium.57 Onyeji et al, demonstrate that GM-CSF 
treatment  augments the antibacterial  activity of macrolides in killing M. avium.58 Kim recently 
demonstrated that patients with NTM pulmonary disease (NTM-PD) had increased levels of anti-GM CSF 
antibodies versus controls  suggestive of  a possible mechanism for the  requirement of exogenous GM-
CSF.59 Pulmonary alveolar proteinosis is a rare lung disease characterised by the presence of anti-GM CSF 
antibodies for which replacement treatment  is already in clinical use. GM-CSF is therefore one area where 
rapid trial development is possible.59 
 
The role of GM-CSF is not limited to Mycobacteria.  GM CSF deficient mice show an increased susceptibility 
to P. aeruginosa infection and defective alveolar macrophage phagocytosis, killing and hydrogen peroxide 
generation.60 GM-CSF enhances neutrophil phagocytosis and bacterial killing in critical illness. Ruchaud-
Sparagano reported that the addition of GM-CSF to neutrophils from bronchiectasis patients  induced  
increases in superoxide generation and the phagocytosis of zymosan.33 Whether such addition  could 
reverse abnormalities in diseased airway neutrophils is unknown and requires investigation.  
 
Phosphodiesterase-4 (PDE4) inhibitors/ Roflumilast 
There is an important overlap between bronchiectasis and COPD.  Up to 50% of bronchiectasis patients 
meet spirometric criteria for COPD and up to 60% of patients with severe COPD meet radiological criteria 
for bronchiectasis.3 The situation is complex as airflow obstruction in bronchiectasis often arises in the 
absence of cigarette smoking and likely follows a different pathophysiology to that in traditional COPD.  
Conversely, not all radiological dilatation in COPD is likely to be clinically significant. 
Nevertheless, there is interest in whether therapeutic concepts in COPD will be transferable to some 
patients with bronchiectasis. Roflumilast is a broad-spectrum anti-inflammatory agent that reduces 
exacerbations in patients with COPD with chronic bronchitis and a high baseline frequency of 
exacerbations.61 Since chronic bronchitis is also a characteristic feature of bronchiectasis, there is some 
logic to considering this for bronchiectasis. There is little other clinical or in-vitro data, however, to support 
the concept directly in bronchiectasis.62 59 
 
Statins 
Statins modulate the innate and adaptive immune systems and have powerful anti-inflammatory effects 
that underlie their benefit in cardiovascular disease.63 Mouse models show that statin administration 
protects against multiple bacterial infections.63 2 RCTs of statins have been performed in bronchiectasis, 
both single centre UK studies.64,65 In the first, atorvastatin 80mg daily was compared to placebo over 6 
months in 60 patients. Statin therapy resulted in a 2.2 unit improvement in the Leicester cough 
questionnaire (LCQ), but was also associated with a significant increase in adverse effects (33% vs 10%).64 
This study enrolled only patients without chronic P. aeruginosa infection and so a second study was 
performed in more severe patients with P. aeruginosa. This study was a cross-over trial of 27 patients 
using the same atorvastatin dose. The primary outcome of improvement in LCQ was not met (mean 
difference 1.92) but there was a significant improvement in SGRQ.64 The mechanism of apparent statin 
benefits is unclear as the first study reported increases in neutrophil apoptosis while the second trial 
reported reduced neutrophil activation in statin treated patients.63,64 Whether these observations are 
clinically relevant remains to be established. The small sample size of these trials, the inconsistent clinical 
benefit and the increased rate of adverse events has led to a recommendation against their use in the 
recent ERS guidelines. Further larger and more focused studies are needed.4 
 
 
Targeting mucociliary clearance and cough 
Airway clearance exercises are the mainstay of therapy in bronchiectasis because it is believed that natural 
mucociliary clearance is impaired.4 Novel therapies enhancing mucociliary function, mucus hydration and 
reducing symptoms would be of great clinical value. Therapies used in practice such as hypertonic or 
isotonic saline, or cysteine derivatives, are supported by minimal data.4 A large UK trial of hypertonic 
saline and carbocisteine will commence in 2018 and may provide the necessary supporting data. 
 
There is limited data on the extent and mechanisms of epithelial dysfunction in bronchiectasis which limits 
the development of therapies that target this aspect of disease. This is an area of intense study in CF, 
where CFTR corrector therapy is now implemented in clinical practice with striking results, and ion channel 
targeting therapies are in clinical development.66 The clinical trials registry identifies a single study 
proposing the use of CFTR correctors or ENAC inhibitors in bronchiectasis, specifically in the context of 
primary ciliary dyskinesia.67 Some bronchiectasis patients have impaired cystic fibrosis transmembrane 
regulator (CFTR) function that does not meet the diagnostic criteria for CF. The importance of CFTR 
mutations in “non-CF” bronchiectasis is controversial. . A Spanish study found CFTR mutations in 36% of 
patients.68 while French work measured nasal potential differences (NPD) in 122 patients with idiopathic 
bronchiectasis and a normal sweat test. They found that CFTR mutations were common in patients with 
bronchiectasis and patients with CFTR mutations and abnormal NPDs were more likely to have 
Staphylococcus aureus and P. aeruginosa infection, organisms classically associated with CF.69 A key 
limitation of this study is the lack of generalizability as the average age of the cohort (45 years) is 
approximately 20 years younger than most European bronchiectasis cohorts. Additionally, the majority of 
patients developed symptoms in early adulthood suggestive of an enrichment for patients more likely to 
have a CFTR related disorder. In contrast King et al found only 4 CFTR mutations in 100 non-CF 
bronchiectasis patients, which is precisely the frequency  predicted from the Caucasian carrier frequency 
of 1 in 25.70 They therefore concluded no role for classical CFTR mutations in idiopathic bronchiectasis. 
It is, however, likely that CFTR dysfunction plays some role in a proportion of non-CF bronchiectasis 
patients and therefore it is of interest to determine if CFTR correction in those carrying pathogenic 
mutations can be attempted using drugs such as ivacaftor, lumicaftor or the emerging 
potentiator/correctors. It is also known that acquired CFTR dysfunction may occur in the absence of CFTR 
mutations in chronic lung disease, a concept best characterised with cigarette smoke exposure.71 It is not 
known but is theoretically possible that CFTR correctors would be effective in the absence of genetic 
mutations if CFTR dysfunction at the epithelial level was demonstrable in bronchiectasis. Of immediate 
concern for clinical care and clinical trials is to ensure that CF is appropriately excluded in patients with 
bronchiectasis. Current guidelines recommend two measurements of sweat chloride and CFTR mutation 
analysis in adults and children under 40 and those over 40 with clinical features of CF.5 
 
ENaC inhibitors aim to rehydrate mucus by preventing sodium hyperabsorption via the ENaC channel, 
implicated in the dehydration of CF airway surface liquid.72 The extent to which mucus hydration is an 
issue in “non-CF” bronchiectasis or whether airway hydration can help to overcome the fundamental cilia 
defects in PCD remain to be fully evaluated before any logical basis for clinical testing can be pursued. 
 
The need for a personalized approach: understanding bronchiectasis and appropriately targeting 
therapy  
Bronchiectasis is an active field for therapeutic development in areas beyond the treatment of chronic 
airway infection with antibiotics.(figure 1) Nevertheless, it is likely that no single therapeutic approach will 
be effective in all patient groups, lessons that should be heeded from other chronic inflammatory lung 
diseases such as severe asthma and pulmonary fibrosis.73,74 The clinical and molecular heterogeneity of 
bronchiectasis must be urgently addressed through detailed endophenotyping studies that will likely 
permit an improved patient stratification and translate to better clinical trial designs and outcomes. Our 
current approach to understanding patients groups in bronchiectasis is simplistic. Individual parameters 
are associated with individual outcomes, for example P. aeruginosa infection is associated with mortality 
and hospital admission risk75, while NTM infection is associated with middle lobe disease.56 Nevertheless, 
even within these groups there is marked heterogeneity that is unresolved and therefore this approach, 
depicted in figure 2, results in large gaps in knowledge and does not directly lead to effective targeting of 
therapies.  None of the links suggested in figure 2 are specific – for example neutrophilic inflammation 
becomes more common and more intense as disease becomes more severe, but neutrophils are also 
found in patients with mild disease.30 We argue that this current approach is unlikely to lead to effective 
targeted therapy. 
 
 
Endophenotyping in bronchiectasis using systems biology, multiomics and the microbiome as a 
gateway to precision medicine 
Patient stratification and the derivation of endophenotypes of clinical relevance may be based on a variety 
of different variables.  The cell-based origin of airway inflammation is a logical start: the majority of 
patients with bronchiectasis are dominated by chronic airway neutrophilic infiltration however a minority, 
up to 1 in 5 illustrate eosinophilic predominance.76, Larger studies of this latter group are required 
particularly with the increasing availability of drugs targeting eosinophil recruitment and function 
including anti-IL5 and anti-IL13 agents in addition to more traditional inhaled corticosteroids.77 
 
Our microbiota are in a constant state of fluidity; changing daily through the foods we eat, the 
environments we live and even people we live and work with.1 The implications of such change is poorly 
understood even in the healthy lung and yet to be studied in bronchiectasis. Despite this, there is already 
a great deal of information available regarding the microbiome in bronchiectasis. Relative abundance and 
load of pathogens like Haemophilus and Pseudomonas spp. are linked to neutrophilic inflammation.31 
Rogers, however, showed that patients with Veillonella predominance had frequent exacerbations 
despite lower levels of neutrophilic inflammation.78 This data clearly hints at a “non-infected” frequent 
exacerbating population that is unlikely to respond to antibiotic therapy but may respond to alternate 
forms of immunomodulatory or mucoactive approaches. A limitation of existing microbiota studies is that 
they predominantly study microbes in isolation, whereas studies that link the microbiota to patient’s 
immunology or other clinical characteristics are more informative31 We therefore advocate a systems 
biology and multi-omics approach to attempt to integrate microbiological, inflammatory and phenotypic 
information in unique way that will allow true patient endotypes to emerge in an unbiased way; 
endotypes with amenability to targeted therapeutic intervention.41 Of all the clinical phenotyping studies 
performed in bronchiectasis to date, the only commonality between them was the emergence of a group 
dominated by the presence of P. aeruginosa which confers poorer prognosis.75.78 Superimposing 
immunological, inflammatory and other patterns derived by multiomic approaches including proteomics, 
transcriptomics and metabolomics will provide even greater clarity and more precision to identifying 
subgroups of patients with bronchiectasis that  appear  similar clinically but are fundamentally different. 
This will influence individual disease trajectory and potentially response to tested therapies. Several 
important areas remain largely unexplored in bronchiectasis, there are few large genetic studies outside 
of CF and PCD, and no studies exploring epigenetics.80,81  
 
Precision medicine holds great promise for bronchiectasis: an approach aiming to individualise 
therapeutic intervention based on multiomic datasets and, integrating this with type and severity of the 
disease, together with the potential response of an individual patient to a particular treatment regimen. 
Despite its potential, many challenges exist to ensure it fulfils its promise. With the wide availability of 
molecular and sequencing technologies that can be applied to the airway we must remain cognisant of 
the risk of ‘getting lost in big data’. To ensure successful translatability of the promise of precision 
medicine, we must understand its greatest challenges for bronchiectasis. These include clinical challenges 
such as the current lack of disease signatures and uncertain numbers of patients and samples required 
for robust analyses.  Methodological challenges include a lack of appropriate analytical tools providing the 
reproducibility and replicability required; this includes difficulties integrating multiomic datasets through 
existing and rather restrictive bioinformatic platforms. To date there are few studies utilising statistical 
clustering or data reduction methods to provide comprehensive endotypes. Widely used examples 
include K-means clustering, latent class analysis and principle component analysis.79,82,83  
 
At the patient level, wide geographical and ethnic variation in bronchiectasis exists and may be one of the 
key challenges.  High rates of post-infectious related disease in Asia, the enrichment for bronchiectasis in 
indigenous populations in the Pacific, a great NTM burden in the Americas and idiopathic disease 
predominating across Europe are a few examples.84 These have been comprehensively reviewed 
elsewhere however such aetiological, microbiological and ethic variation brings about questions related 
to disease phenotyping and potential endotyping studies that must be considered. Why is disease more 
severe at a younger age in Asia? What are the environmental and climatic effects on disease, the airway 
microbes, infection and the microbiome across regions? What is the impact of innate immune variation 
on disease? The experience of the RESPIRE 1 and 2 trials, where a study performed predominantly in Asia 
and Eastern Europe encountered patients with apparently more severe disease but a lower frequency of 
exacerbations, apparently resulting in discordant trial results, emphasises how important it is to now 
understand these variations on patient’s characteristics.21 
International disease registries such as the European Multicentre Audit and Research Collaboration 
(EMBARC) which has enrolled >11000 patients worldwide since 2015, the United States Bronchiectasis 
Research Registry, and similar initiatives in Australia and India are likely in the next 2-3 years to resolve 
much of the clinical heterogeneity and allow a great understanding of patient subtypes as well as 
facilitating recruitment to randomized trials.7,8,85 Linking these initiatives with translational research 
should now be a priority.  
 
Treatable traits 
Experts in COPD and asthma recently advocated the use of the term “Treatable traits” to describe the 
spectrum of manifestations of airway disease.71 Within this definition, the authors included bronchiectasis 
as a potential “treatable trait”. Here we expand this concept to suggest that within bronchiectasis there 
are also multiple potentially “treatable traits” in individuals with the disease, many of which remain 
unexplored and untested and, represent a rich source for future work in the field (figure 3). This concept 
embraces the idea that patients can have multiple treatable traits, and may therefore require complex 
multicomponent interventions. In addition, endophenotyping approaches accumulate a list of potential 
“targetable traits” aspects of the biology of bronchiectasis amenable to therapeutic intervention using 
existing or repurposed drugs which have been discussed in this review. (figure 3) 
 
 
Conclusions 
If this is to be truly “the age of bronchiectasis” therapeutic development must move beyond antibiotics 
and towards an endophenotyping  guided precision medicine approach incorporating 
immunomodulatory, antimicrobial, mucoactive and disease modifying drugs that target carefully defined 
patients groups and potentially better clinical trial outcomes.  
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Summarized recommendation Strength of 
recommendation 
Quality of 
evidence 
Perform a minimum bundle of tests including differential blood 
count, serum immunoglobulins, and testing for ABPA in newly 
diagnosed patients 
Conditional Very low 
Treat acute exacerbations of bronchiectasis with 14 days of 
antibiotics 
Conditional Very low 
Patients with a new isolation of Pseudomonas aeruginosa should 
be offered eradication antibiotic treatment 
Conditional Very low 
Do not offer eradication antibiotic treatment to patients 
following new isolation of pathogens other than P. aeruginosa. 
Conditional Very low 
Do not offer inhaled corticosteroids for the treatment of 
bronchiectasis  
Conditional  Low 
Do not offer statins for the treatment of bronchiectasis Strong Low 
Offer long term antibiotic treatment for patients with three or 
more exacerbations per year* 
Conditional Moderate 
Offer mucoactive treatment for patients with  difficulty 
expectorating sputum and poor quality of life where standard 
airway clearance techniques have failed to control symptoms 
Conditional Low 
Do not offer recombinant DNase for the treatment of 
bronchiectasis 
Strong Moderate 
Do not routinely offer long acting bronchodilators for patients 
with bronchiectasis  
Conditional Very low 
Offer long acting bronchodilators for patients with significant 
breathlessness on an individual basis 
Conditional Very low 
Do not offer surgical treatments with the exception of patients 
with localised disease and high exacerbation frequency despite 
optimal medical care 
Conditional  Very low 
Patients with chronic productive cough or difficulty  
expectorating  should be taught airway clearance techniques  
Conditional Low 
Patients with impaired exercise capacity should participate in 
pulmonary rehabilitation and take regular exercise 
Strong High 
Table 1. Summary of recommendations from the recent European Respiratory Society guidelines for the 
management of adult bronchiectasis.4 Guideline recommendations have been modified from their original 
wording for brevity and clarity. *additional recommendations are made relating to circumstances where 
inhaled, oral or macrolide antibiotics may be used. Please refer to the guidelines for full details.4  
  
Investigational drug Phase  Trial design 
Primary 
outcome/objective 
Duration 
Number 
of 
patients 
Single or 
Multicentre 
Location 
Current 
status 
Trial 
registration 
number 
Recombinant GM-
CSF 
I 
Single and multiple 
ascending dose 
studies in healthy 
subjects 
Safety 28 days 42 Single , UK Completed NCT02468908 
Human 
Mesenchymal Stem 
cells 
I 
Non-randomized 
safety evaluation 
Safety 
Single infusion 
with up to 48 
week follow-up 
6 Single Miami, USA Recruiting NCT02625246 
Neutrophil elastase 
inhibitor: CHF6333 
I 
Single and multiple 
ascending dose 
studies in healthy 
subjects 
Safety 15 days 72 Single Belgium Completed NCT03056326 
Cathepsin-C 
inihibitor 
I 
Single and multiple 
ascending dose 
studies in healthy 
subjects 
Safety 18 days 33 Single  UK Completed NCT02058407 
GSK2793660 
Cathepsin-C 
inihibitor INS1007 
II 
Double blind 
randomized 
placebo controlled 
trial 
Time to the first 
exacerbation 
24 weeks 240 Multi-centre  Worldwide 
Not yet 
recruiting 
NCT03218917 
Roflumilast II Open label trial Change in CASA-Q 16 weeks 25 Single 
South 
Korea 
Unknown NCT01580748 
N-aceylcysteine III 
Randomized, open 
label 
Frequency of acute 
exacerbations 
12 months 150 Single China Recruiting NCT02088216 
ENaC inhibitor* III 
Randomized 
crossover study 
Change in FEV1 and 
safety 
28 days 150 Multi-centre Worldwide Recruiting NCT02871778 
Theophylline III 
Randomized 
blinded placebo 
controlled trial 
St Georges 
Respiratory 
Questionnaire 
24 weeks 100 Single China Completed NCT01684683 
Vitamin-D III 
Randomized 
blinded placebo 
controlled trial 
Time to first 
exacerbation 
1 year 200 Single China Unknown 
NCT02507843 
(retrospectively 
registered) 
Neutrophil elastase 
inhibitor: BAY85-
8501 
III 
Randomized 
double blind 
placebo controlled 
trial 
Safety 56 days 94 Multi-centre Worldwide Completed NCT01818544 
OM-85 (extracted of 
multiple bacteria) 
III 
Randomized 
placebo controlled 
trial 
Percentage of 
patients free from 
exacerbations 
1 year 244 Multi-centre  China Recruiting NCT01968421 
Table 2. Summary of selected randomized controlled trials registered in public databases which are 
active, recruiting or completed but not yet published. We have only included studies not evaluating 
antibiotics and studying stable patients with bronchiectasis or studies of novel drugs in healthy subjects 
where the term bronchiectasis was included in the registration indicating these patients as the target 
population. *specific for patients with bronchiectasis due to primary ciliary dyskinesia. 
  
Figure Legends 
 
Figure 1: A summary of emerging therapies for bronchiectasis in active clinical development.  
 
Figure 2: Current classification of bronchiectasis. The figure demonstrates that patients can be classified into 
multiple different subcategories based on multiple characteristics. Characteristics that have been well studied and 
linked to clinical outcomes (boxed pink) and those that have been studied but have not been linked with a specific 
outcome or clinical phenotype (boxed grey) are illustrated.  
 
Figure 3: Bronchiectasis ‘traits’ divided into those ‘treatable’ with current therapies (left hand panel), ‘targetable’ 
through future endo-phenotyping approaches (right hand panel) and ‘other factors’ recognized to have potential 
effects on bronchiectasis (bottom panel). 
 
